Alkem Laboratories has been issued a Form 483 with seven observations following an inspection by the US Food and Drug Administration (FDA) at its manufacturing facility in Amaliya, Daman. The inspection took place from 20th April to 1st May 2026.
The Form 483 is a document issued by the FDA to notify a company of conditions that may violate the Food Drug and Cosmetic (FD&C) Act and related regulations. Receiving such a form indicates that the FDA has found certain areas of concern during its inspection that need to be addressed.
Alkem Laboratories has stated that it will address the observations within the stipulated timeframe, although specific details of the observations have not been disclosed. The company is expected to respond with a corrective action plan to ensure compliance with FDA regulations.
The issuance of a Form 483 can have significant implications for pharmaceutical companies, as it may affect their ability to manufacture and distribute products in the US market if not adequately addressed.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).